Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medic... ( SAN DIEGO Nov. 21 /- Gen-Probe's (Nas...)

Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medical Meeting

Date:11/21/2008

SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Gen-Probe's (Nasdaq: GPRO) CE-marked APTIMA(R) HPV assay may be an important new molecular tool to more accurately detect high-risk human papillomavirus (HPV) infections that are associated with cervical cancer or precancerous lesions, according to nine oral presentations and two scientific posters presented last week by independent and Gen-Probe researchers at the international conference of the European Research Organization on Genital Infection and Neoplasia (EUROGIN) in Nice, France.

Gen-Probe's APTIMA HPV assay has been CE-marked for sale in the European Union, and clinical trials of the test are underway in the United States. The assay has not been approved for marketing by the U.S. Food and Drug Administration.

"As a whole, these studies suggest that our new APTIMA HPV assay may detect high-risk HPV infections that have progressed, or are progressing, to cervical cancer more specifically than competing assays that simply detect whether HPV infection is present," said Dan Kacian, Ph.D., M.D., Gen-Probe's executive vice president and chief scientist. "Since most HPV infections resolve without causing cancer, more specific tests are needed to avoid unnecessary and invasive medical procedures and patient anxiety. Additional longer-term studies are needed and are underway, but these results give us continued confidence that our test may play an important role in helping protect women from both cervical cancer and the adverse effects of non- specific diagnosis."

In one key presentation at EUROGIN, Joseph Monsonego, M.D., EUROGIN scientific director, presented interim results of the French APTIMA HPV Screening Evaluation (FASE) study from 1,528 women. The study eventually will include 5,000 women between the ages of 20 and 65. In the study, liquid cytolog
'/>"/>

2

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Drugs from Johnson & Johnson/Basilea and Forest Are the Most Promising Antibiotics in the Community-Acquired Pneumonia Pipeline
2. Promising Data ATIR Studies Presented by NIH Investigators
3. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
4. Victhom announces promising results on the proof of concept for its unique closed-loop neuromodulation system
5. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
6. Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
7. AMDL ELISA DR-70(R) (FDP) is Promising as Effective Cancer Detection Test
8. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
9. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound

Post Your Comments:

Promising Clinical Data on Gen-Probe's APTIMA(R) HPV Test Presented at Major European Medic...( SAN DIEGO Nov. 21 /- Gen-Probe's (Nas...)